Patient-Derived Models

Established cancer cell lines have supported oncology drug development for decades and remain the fastest route to an interpretable in vivo result. What they cannot supply is the biology that makes one patient respond to a therapy while another does not. Lines maintained indefinitely in culture undergo clonal selection and transcriptional divergence, lose stromal and immune context, and converge on a phenotype that no longer represents the tumor they came from.

Patient-derived models retain that heterogeneity by working directly with tumor material from individual donors. Altogen Labs supports patient-derived tumor organoids for ex vivo expansion and screening, patient-derived cells for assay work requiring primary material, three-dimensional tumor models that reconstruct architecture and gradients absent from monolayer culture, and patient-derived xenograft models for in vivo studies.

Altogen Labs maintains an IACUC-regulated animal facility and has conducted patient-derived and cell line derived oncology studies for pharmaceutical, biotechnology, and academic clients internationally. Company scientists have published on xenograft model selection and standardization, including the reporting frameworks that govern how patient-derived models should be documented.

Where each platform fits

Patient-derived tumor organoids are three-dimensional cultures established from tumor tissue that retain much of the architecture and differentiation state of the donor epithelium. Their principal advantage is throughput from limited input: a biopsy that would support only a single in vivo arm can, after organoid expansion, support a screening cascade followed by in vivo validation of the candidates that emerge. This matters most where tissue is scarce and committing the entire sample to one experiment is unacceptable.

Patient-derived cells provide primary material for assay work where an established line would not represent the relevant biology, including cytotoxicity testing, target expression profiling, and mechanistic work in a genetic background matching a specific donor.

Three-dimensional tumor models reconstruct features monolayer culture eliminates: cell-cell contact in three dimensions, nutrient and oxygen gradients, and a proliferative gradient between surface and interior. Compounds whose activity depends on penetration, or whose mechanism is sensitive to hypoxia or quiescent populations, frequently behave differently in three dimensions, and that difference is informative rather than artifactual.

Patient-derived xenografts engraft tumor tissue directly into immunodeficient hosts with no intervening culture step, preserving donor histology, genomic architecture, and intratumoral heterogeneity across early passages. Orthotopic implantation is available through PDOX models, difficult-to-engraft tumor types through subrenal capsule implantation, and immuno-oncology applications through humanized PDX. Organoid-derived xenografts bridge the ex vivo and in vivo stages within one program.

To discuss which platform fits a program, request a quote.

Working with patient material

Patient-derived work carries operational constraints established lines do not. Tissue viability declines from the moment of resection, so transport conditions and the interval between collection and processing materially affect whether a model establishes at all. Institutional review board approval and written informed consent are mandatory for all patient-derived material, and provenance documentation is maintained throughout.

Establishment is not guaranteed for any individual sample, and success rates differ substantially between tumor types. Aggressive, poorly differentiated, and treatment-resistant tumors establish more readily than indolent, well-differentiated disease. Program planning should account for this at the outset rather than assume a fixed yield, and study design should specify what happens if a given sample fails to establish.

Applied examples

Screening then validation. Organoids established from a colorectal biopsy are expanded and screened against a panel of candidate agents, and the two most active compounds are progressed into organoid-derived xenografts from the same line, so the in vivo confirmation is performed in matched genetic background rather than a surrogate.

Resistance modeling. Tumor tissue collected after clinical progression on a targeted agent is engrafted directly, producing a model that carries the resistance biology that actually arose in the patient, and is then used to test whether a next-line candidate retains activity.

Donor-matched immuno-oncology. A patient-derived tumor and immune cells from the same donor are engrafted together, eliminating MHC mismatch between tumor and immune compartments, and a checkpoint inhibitor is evaluated against tumor response with parallel immune profiling.

Translational applications

Patient-derived platforms support biomarker discovery and validation, where the object is to identify which molecular feature predicts response; resistance and relapse modeling; and personalized oncology applications in which a model derived from an individual donor is tested against a panel of candidate therapies.

Documentation, ethics, and reporting

Patient-derived work is only reproducible if it is documented. Altogen Labs records tumor source, clinical annotation where provided, host background, implantation site, passage number, and engraftment outcome for every model, consistent with established minimal information reporting standards for patient-derived xenografts. Institutional review board approval and written informed consent are prerequisites for all human tissue. All animal procedures are conducted under active IACUC protocols, and GLP standards are applied where a study is formally designated as GLP.

Send program details and tissue availability, or request a quote.